Terms: = Lung cancer AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Prognosis
35 results:
1. Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma.
Deng Z; Cui L; Li P; Ren N; Zhong Z; Tang Z; Wang L; Gong J; Cheng H; Guan Y; Yi X; Xia X; Zhou R; He Z
Cell Death Dis; 2021 Oct; 12(10):935. PubMed ID: 34642306
[TBL] [Abstract] [Full Text] [Related]
2. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
[TBL] [Abstract] [Full Text] [Related]
3. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
[No Abstract] [Full Text] [Related]
4. Investigation of Targeting Relationship between Micro-Rna-22 and vegfr3 in lung Squamous Cell Carcinoma.
Dong Z; Xu QH; Zhu YB; Wang YF; Xiong J; Dang S
Comb Chem High Throughput Screen; 2021; 24(1):148-154. PubMed ID: 32691705
[TBL] [Abstract] [Full Text] [Related]
5. [High expression of vegfr3 is positively associated with poor prognosis in lung adenocarcinoma].
Li J; Zhang W; Xia H; Liu Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Nov; 35(11):1023-1029. PubMed ID: 31878999
[TBL] [Abstract] [Full Text] [Related]
6. Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.
Alcala N; Mangiante L; Le-Stang N; Gustafson CE; Boyault S; Damiola F; Alcala K; Brevet M; Thivolet-Bejui F; Blanc-Fournier C; Le Rochais JP; Planchard G; Rousseau N; Damotte D; Pairon JC; Copin MC; Scherpereel A; Wasielewski E; Wicquart L; Lacomme S; Vignaud JM; Ancelin G; Girard C; Sagan C; Bonnetaud C; Hofman V; Hofman P; Mouroux J; Thomas de Montpreville V; Clermont-Taranchon E; Mazieres J; Rouquette I; Begueret H; Blay JY; Lantuejoul S; Bueno R; Caux C; Girard N; McKay JD; Foll M; Galateau-Salle F; Fernandez-Cuesta L
EBioMedicine; 2019 Oct; 48():191-202. PubMed ID: 31648983
[TBL] [Abstract] [Full Text] [Related]
7. A facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized pcl nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers.
Parashar P; Tripathi CB; Arya M; Kanoujia J; Singh M; Yadav A; Saraf SA
Drug Deliv Transl Res; 2019 Feb; 9(1):37-52. PubMed ID: 30178279
[TBL] [Abstract] [Full Text] [Related]
8. Lymphatic vessel density as a prognostic indicator in Asian NSCLC patients: a meta-analysis.
Xu S; Yang J; Xu S; Zhu Y; Zhang C; Liu L; Liu H; Dong Y; Teng Z; Xing X
BMC Pulm Med; 2018 Aug; 18(1):128. PubMed ID: 30081883
[TBL] [Abstract] [Full Text] [Related]
9. vegfr3 inhibition chemosensitizes lung adenocarcinoma A549 cells in the tumor-associated macrophage microenvironment through upregulation of p53 and PTEN.
Li Y; Weng Y; Zhong L; Chong H; Chen S; Sun Y; Li W; Shi Q
Oncol Rep; 2017 Nov; 38(5):2761-2773. PubMed ID: 29048623
[TBL] [Abstract] [Full Text] [Related]
10. High expression of C-X-C chemokine receptor 4 and Notch1 is predictive of lymphovascular invasion and poor prognosis in lung adenocarcinoma.
Cong Z; Wu H; Guo Z; Qin T; Xu Y; Jing H; Wang Y; Shen Y
Tumour Biol; 2017 Jun; 39(6):1010428317708698. PubMed ID: 28618922
[TBL] [Abstract] [Full Text] [Related]
11. De Novo Computational Design for Development of a Peptide Ligand Oriented to VEGFR-3 with High Affinity and Long Circulation.
Li HM; Dong ZP; Wang QY; Liu LX; Li BX; Ma XN; Lin MS; Lu T; Wang Y
Mol Pharm; 2017 Jul; 14(7):2236-2244. PubMed ID: 28506066
[TBL] [Abstract] [Full Text] [Related]
12. [The Current Immunohistochemistry Markers in the Resected Tissues of Non-small Cell lung cancer Could Not Predict prognosis].
Shen L; Kang X; Sun Y; Fu H; Dai L; Yan W; Chen K
Zhongguo Fei Ai Za Zhi; 2016 Mar; 19(3):147-52. PubMed ID: 27009819
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis.
Zheng CL; Qiu C; Shen MX; Qu X; Zhang TH; Zhang JH; Du JJ
Asian Pac J Cancer Prev; 2015; 16(5):1881-95. PubMed ID: 25773840
[TBL] [Abstract] [Full Text] [Related]
14. Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects.
Chang YW; Su CM; Su YH; Ho YS; Lai HH; Chen HA; Kuo ML; Hung WC; Chen YW; Wu CH; Chen PS; Su JL
Oncotarget; 2014 Jun; 5(11):3823-35. PubMed ID: 25003617
[TBL] [Abstract] [Full Text] [Related]
15. Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model.
Quagliata L; Klusmeier S; Cremers N; Pytowski B; Harvey A; Pettis RJ; Thiele W; Sleeman JP
Clin Exp Metastasis; 2014 Mar; 31(3):351-65. PubMed ID: 24379135
[TBL] [Abstract] [Full Text] [Related]
16. E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.
Ogino H; Hanibuchi M; Kakiuchi S; Trung VT; Goto H; Ikuta K; Yamada T; Uehara H; Tsuruoka A; Uenaka T; Wang W; Li Q; Takeuchi S; Yano S; Nishioka Y; Sone S
Mol Cancer Ther; 2011 Jul; 10(7):1218-28. PubMed ID: 21551260
[TBL] [Abstract] [Full Text] [Related]
17. Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients.
Anagnostou VK; Tiniakos DG; Fotinou M; Achimastos A; Syrigos KN
Virchows Arch; 2011 Mar; 458(3):331-40. PubMed ID: 21161269
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis.
Zhan P; Wang J; Lv XJ; Wang Q; Qiu LX; Lin XQ; Yu LK; Song Y
J Thorac Oncol; 2009 Sep; 4(9):1094-103. PubMed ID: 19687765
[TBL] [Abstract] [Full Text] [Related]
19. Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer.
Donnem T; Al-Saad S; Al-Shibli K; Busund LT; Bremnes RM
Ann Oncol; 2010 Feb; 21(2):223-231. PubMed ID: 19628565
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
[TBL] [Abstract] [Full Text] [Related]
[Next]
